Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SALVIANOLIC ACID B | ? unclear | Mechanistic | DGIdb | |
| CANDOXATRIL | ? unclear | Mechanistic | DGIdb | |
| CILAZAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| TP0556351 | ↓ inhibits | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| SILDENAFIL | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| RESCINNAMINE | ? unclear | Mechanistic | DGIdb | |
| SPIRAPRIL | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ? unclear | Mechanistic | DGIdb | |
| ARGIPRESSIN | ? unclear | Mechanistic | DGIdb | |
| METOPROLOL | ? unclear | Mechanistic | DGIdb | |
| DELAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| ACETYLCHOLINE | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| IMIDAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| MALATHION | ↓ inhibits | Mechanistic | DGIdb | |
| MOEXIPRIL | ? unclear | Mechanistic | 56.0 nM (IC50) | DGIdb |
| VORINOSTAT | ? unclear | Mechanistic | DGIdb | |
| ILEPATRIL | ↓ inhibits | Mechanistic | DGIdb | |
| RXP470.1 | ↓ inhibits | Mechanistic | DGIdb | |
| CGS-27023A | ? unclear | Mechanistic | DGIdb | |
| NITROPRUSSIDE | ? unclear | Mechanistic | DGIdb | |
| ENALAPRILAT ANHYDROUS | ↓ inhibits | Mechanistic | 1.2 nM (IC50) | DGIdb |
| TORSEMIDE | ? unclear | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| FOSINOPRIL | ? unclear | Mechanistic | DGIdb | |
| FUROSEMIDE | ? unclear | Mechanistic | DGIdb | |
| TEMOCAPRIL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| BENAZEPRIL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CARBARIL | ↓ inhibits | Mechanistic | DGIdb | |
| BUPROPION HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| QUINAPRIL | ? unclear | Mechanistic | 8.3 nM (IC50) | DGIdb |
| COMPOUND 1 [PMID: 24900526] | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 20 [PMID: 22153340] | ↓ inhibits | Mechanistic | DGIdb | |
| BUMETANIDE | ? unclear | Mechanistic | DGIdb | |
| GALLOPAMIL | ? unclear | Mechanistic | DGIdb | |
| FLUOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| AZD6605 | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 229 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FACTOR IX | ? unclear | Mechanistic | DGIdb | |
| SSR-126517E | ? unclear | Mechanistic | DGIdb | |
| COAGULATION FACTOR IX | ? unclear | Mechanistic | DGIdb | |
| COAGULATION FACTOR X HUMAN | ? unclear | Mechanistic | DGIdb | |
| LETAXABAN | ? unclear | Mechanistic | DGIdb | |
| IDRAPARINUX | ? unclear | Mechanistic | DGIdb | |
| COAGULATION FACTOR X, HUMAN | ? unclear | Mechanistic | DGIdb | |
| NADROPARIN CALCIUM | ? unclear | Mechanistic | DGIdb | |
| EDOXABAN | ↓ inhibits | Mechanistic | DGIdb | |
| RIVAROXABAN | ↓ inhibits | Mechanistic | DGIdb | |
| THROMBIN | ? unclear | Mechanistic | DGIdb | |
| LY-517717 | ? unclear | Mechanistic | DGIdb | |
| SR-123781A | ? unclear | Mechanistic | DGIdb | |
| ERIBAXABAN | ↓ inhibits | Mechanistic | DGIdb | |
| TRIMETHOPRIM/SULFADOXINE | ? unclear | Mechanistic | DGIdb | |
| HEPARIN | ? unclear | Mechanistic | DGIdb | |
| APIXABAN | ↓ inhibits | Mechanistic | DGIdb | |
| MANGIFERIN HEPTASULFATE | ? unclear | Mechanistic | DGIdb | |
| DX-9065A | ↓ inhibits | Mechanistic | DGIdb | |
| COAGULATION FACTOR VIIA | ? unclear | Mechanistic | DGIdb | |
| EDOXABAN TOSYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| TANOGITRAN | ? unclear | Mechanistic | DGIdb | |
| 2-O, 3-O DESULFATED HEPARIN | ? unclear | Mechanistic | DGIdb | |
| BAY 3389934 | ↓ inhibits | Mechanistic | DGIdb | |
| FACTOR VIII | ? unclear | Mechanistic | DGIdb | |
| SEMULOPARIN | ? unclear | Mechanistic | DGIdb | |
| IDRABIOTAPARINUX SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| ANDEXANET ALFA | ? unclear | Mechanistic | DGIdb | |
| BEMIPARIN | ↓ inhibits | Mechanistic | DGIdb | |
| VITAMIN K3 | ? unclear | Mechanistic | DGIdb | |
| DAREXABAN | ↓ inhibits | Mechanistic | DGIdb | |
| ANTITHROMBIN III | ? unclear | Mechanistic | DGIdb | |
| FONDAPARINUX | ? unclear | Mechanistic | DGIdb | |
| PROTHROMBIN COMPLEX CONCENTRATE | ? unclear | Mechanistic | DGIdb | |
| DANAPAROID | ? unclear | Mechanistic | DGIdb | |
| GW-813893 | ? unclear | Mechanistic | DGIdb | |
| IDRAPARINUX SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| BETRIXABAN | ↓ inhibits | Mechanistic | DGIdb | |
| NONACOG ALFA | ? unclear | Mechanistic | DGIdb | |
| EP-217609 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 242 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DESIRUDIN | ↓ inhibits | Mechanistic | DGIdb | |
| BIVALIRUDIN | ↓ inhibits | Mechanistic | DGIdb | |
| TAMOXIFEN | ? unclear | Mechanistic | DGIdb | |
| PEGMUSIRUDIN | ? unclear | Mechanistic | DGIdb | |
| FLOVAGATRAN | ? unclear | Mechanistic | DGIdb | |
| ANISINDIONE | ? unclear | Mechanistic | DGIdb | |
| HEPARIN | ? unclear | Mechanistic | DGIdb | |
| CATECHIN | ? unclear | Mechanistic | DGIdb | |
| DABIGATRAN | ↓ inhibits | Mechanistic | DGIdb | |
| DABIGATRAN ETEXILATE MESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| QUERCETIN | ? unclear | Mechanistic | DGIdb | |
| ODIPARCIL | ? unclear | Mechanistic | DGIdb | |
| DPOC-4088 | ? unclear | Mechanistic | DGIdb | |
| LUSUTROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| ICHORCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PYRIDOXAL PHOSPHATE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| BORTEZOMIB | ? unclear | Mechanistic | 13000.0 nM (Ki) | DGIdb |
| ANTITHROMBIN ALFA | ↓ inhibits | Mechanistic | DGIdb | |
| SR-123781A | ? unclear | Mechanistic | DGIdb | |
| ENOXAPARIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| CYANIDIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL586628 | ? unclear | Mechanistic | DGIdb | |
| AZD-8165 | ? unclear | Mechanistic | DGIdb | |
| STAUROSPORINE | ↓ inhibits | Mechanistic | DGIdb | |
| AVATROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| HIRUDIN | ? unclear | Mechanistic | DGIdb | |
| CYANIN | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 2C [PMID: 24900538] | ↓ inhibits | Mechanistic | DGIdb | |
| SILIBININ | ? unclear | Mechanistic | DGIdb | |
| EP-217609 | ? unclear | Mechanistic | DGIdb | |
| APRAMIDE A | ? unclear | Mechanistic | DGIdb | |
| EPICATECHIN | ? unclear | Mechanistic | DGIdb | |
| ARGATROBAN | ↓ inhibits | Mechanistic | DGIdb | |
| MELAGATRAN | ? unclear | Mechanistic | 4700.0 nM (IC50) | DGIdb |
| ATECEGATRAN METOXIL | ↓ inhibits | Mechanistic | DGIdb | |
| ASPIRIN TRELAMINE | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K3 | ? unclear | Mechanistic | DGIdb | |
| XIMELAGATRAN | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1083499 | ? unclear | Mechanistic | DGIdb | |
| DABIGATRAN ETEXILATE | ? unclear | Mechanistic | Open Targets |
Showing top 40 of 238 agents ranked by evidence tier.
HMGCR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LOVASTATIN | ↓ inhibits | Mechanistic | 37.0 nM (IC50) | DGIdb |
| SIMVASTATIN | ↓ inhibits | Mechanistic | 2.6 nM (Ki) | DGIdb |
| ROSUVASTATIN | ↓ inhibits | Mechanistic | 0.9 nM (Ki) | DGIdb |
| ATORVASTATIN CALCIUM TRIHYDRATE | ↓ inhibits | Mechanistic | DGIdb | |
| FLUVASTATIN | ↓ inhibits | Mechanistic | 28.0 nM (IC50) | DGIdb |
| PRAVASTATIN SODIUM | ↓ inhibits | Mechanistic | 1370.0 nM (IC50) | DGIdb |
| CERIVASTATIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| PITAVASTATIN CALCIUM | ↓ inhibits | Mechanistic | DGIdb | |
| PITAVASTATIN | ? unclear | Mechanistic | DGIdb | |
| TOCOTRIENOLS | ? unclear | Mechanistic | DGIdb | |
| CRILVASTATIN | ? unclear | Mechanistic | DGIdb | |
| ASPIRIN | ? unclear | Mechanistic | DGIdb | |
| PITAVASTATIN MAGNESIUM | ↓ inhibits | Mechanistic | DGIdb | |
| PITAVASTATIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| CERIVASTATIN | ? unclear | Mechanistic | 10.0 nM (IC50) | DGIdb |
| LAROPIPRANT | ? unclear | Mechanistic | DGIdb | |
| TERIFLUNOMIDE | ? unclear | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN | ? unclear | Mechanistic | 30.0 nM (IC50) | Open Targets |
| ROSUVASTATIN CALCIUM | ? unclear | Mechanistic | Open Targets | |
| ATORVASTATIN CALCIUM | ? unclear | Mechanistic | Open Targets | |
| ATORVASTATIN | ? unclear | Mechanistic | 6.0 nM (IC50) | Open Targets |
| FLUVASTATIN SODIUM | ? unclear | Mechanistic | Open Targets | |
| CHEMBL39102 | ↓ inhibits | Mechanistic | 16.0 nM (Ki) | ChEMBL |
| CHEMBL39312 | ↓ inhibits | Mechanistic | 3.0 nM (Ki) | ChEMBL |
| CHEMBL175236 | ↓ inhibits | Mechanistic | 29.0 nM (IC50) | ChEMBL |
| CHEMBL115307 | ↓ inhibits | Mechanistic | 1400.0 nM (IC50) | ChEMBL |
| CHEMBL487720 | ↓ inhibits | Mechanistic | 12.0 nM (IC50) | ChEMBL |
| CHEMBL323880 | ↓ inhibits | Mechanistic | 2220.0 nM (IC50) | ChEMBL |
| CHEMBL11804 | ↓ inhibits | Mechanistic | 3000.0 nM (IC50) | ChEMBL |
| CHEMBL11891 | ↓ inhibits | Mechanistic | 1720.0 nM (IC50) | ChEMBL |
| CHEMBL276717 | ↓ inhibits | Mechanistic | 1290.0 nM (IC50) | ChEMBL |
| CHEMBL162642 | ↓ inhibits | Mechanistic | 0.014 nM (IC50) | ChEMBL |
| CHEMBL159951 | ↓ inhibits | Mechanistic | 0.018 nM (IC50) | ChEMBL |
| CHEMBL345375 | ↓ inhibits | Mechanistic | 6.0 nM (IC50) | ChEMBL |
| CHEMBL159103 | ↓ inhibits | Mechanistic | 5.0 nM (IC50) | ChEMBL |
| CHEMBL2375156 | ↓ inhibits | Mechanistic | 0.83 nM (IC50) | ChEMBL |
| CHEMBL163277 | ↓ inhibits | Mechanistic | 0.27 nM (IC50) | ChEMBL |
| CHEMBL2375155 | ↓ inhibits | Mechanistic | 0.106 nM (IC50) | ChEMBL |
| CHEMBL160102 | ↓ inhibits | Mechanistic | 0.05 nM (IC50) | ChEMBL |
Showing top 40 of 188 agents ranked by evidence tier.
ITGB3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| EPTIFIBATIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ATN-161 | ↓ inhibits | Mechanistic | DGIdb | |
| ABCIXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CYPATE | ? unclear | Mechanistic | DGIdb | |
| INTETUMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| INTEGRIN RECEPTOR ANTAGONIST GLPG0187 | ? unclear | Mechanistic | DGIdb | |
| ZALUNFIBAN | ↓ inhibits | Mechanistic | DGIdb | |
| CILENGITIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ANTI-THYMOCYTE GLOBULIN | ? unclear | Mechanistic | DGIdb | |
| TIROFIBAN HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ABITUZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TIROFIBAN | ? unclear | Mechanistic | DGIdb | |
| GANTOFIBAN | ? unclear | Mechanistic | DGIdb | |
| ETARACIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TADOCIZUMAB | ↓ inhibits | Mechanistic | DGIdb |
P2RY12
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| COMPOUND 4 [PMID: 23083103] | ↓ inhibits | Mechanistic | DGIdb | |
| CLOPIDOGREL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| MC-1 | ? unclear | Mechanistic | DGIdb | |
| PRASUGREL | ? unclear | Mechanistic | DGIdb | |
| 2MESADP | ↑ activates | Mechanistic | DGIdb | |
| TREPROSTINIL | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 58L [PMID: 30843696] | ↓ inhibits | Mechanistic | DGIdb | |
| CLOPIDOGREL | ? unclear | Mechanistic | DGIdb | |
| TICAGRELOR | ↓ inhibits | Mechanistic | 1.995 nM (Ki) | DGIdb |
| AZD1283 | ↓ inhibits | Mechanistic | DGIdb | |
| AR-C67085 | ↓ inhibits | Mechanistic | DGIdb | |
| R-138727 | ↓ inhibits | Mechanistic | DGIdb | |
| CLOPIDOGREL HYDROBROMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ADP | ↑ activates | Mechanistic | DGIdb | |
| PSB-22219 | ↓ inhibits | Mechanistic | DGIdb | |
| TICLOPIDINE | ? unclear | Mechanistic | DGIdb | |
| REGRELOR DISODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| BX 667 | ↓ inhibits | Mechanistic | DGIdb | |
| CYTARABINE | ? unclear | Mechanistic | DGIdb | |
| PRASUGREL BESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]PSB-22219 | ↓ inhibits | Mechanistic | DGIdb | |
| CANGRELOR TETRASODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| CLOPIDOGREL (ACTIVE METABOLITE) | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]AZ12464237 | ↓ inhibits | Mechanistic | DGIdb | |
| INS49266 | ↓ inhibits | Mechanistic | DGIdb | |
| PSB-0739 | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]PSB-0413 | ↓ inhibits | Mechanistic | DGIdb | |
| CLOPIDOGREL BISULFATE | ↓ inhibits | Mechanistic | DGIdb | |
| 2MESAMP | ↓ inhibits | Mechanistic | DGIdb | |
| ELINOGREL | ↓ inhibits | Mechanistic | DGIdb | |
| TICLOPIDINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 20O [PMID: 22984835] | ↓ inhibits | Mechanistic | DGIdb | |
| CANGRELOR | ↓ inhibits | Mechanistic | 0.4 nM (IC50) | DGIdb |
| BX 048 | ↓ inhibits | Mechanistic | DGIdb | |
| ADPΒS | ↑ activates | Mechanistic | DGIdb | |
| PCMBS | ↓ inhibits | Mechanistic | DGIdb | |
| REGRELOR | ↓ inhibits | Mechanistic | 16.0 nM (IC50) | DGIdb |
| COMPOUND 4 [PMID: 22984835] | ↓ inhibits | Mechanistic | DGIdb | |
| PRASUGREL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| SELATOGREL | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 204 agents ranked by evidence tier.
PCSK9
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ALIROCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| ONGERICIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TAFOLECIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LOMITAPIDE MESYLATE | ? unclear | Mechanistic | DGIdb | |
| EVOLOCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| RG-7652 | ↓ inhibits | Mechanistic | DGIdb | |
| BOCOCIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| FROVOCIMAB | ? unclear | Mechanistic | DGIdb | |
| RALPANCIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LERODALCIBEP | ↓ inhibits | Mechanistic | DGIdb | |
| INCLISIRAN | ? unclear | Mechanistic | DGIdb | |
| INCLISIRAN SODIUM | ? unclear | Mechanistic | Open Targets | |
| DIPHENYL BORINIC ACID | ↓ inhibits | Mechanistic | 30000.0 nM (Ki) | ChEMBL |
| PHENYL BUTYL BORINIC ACID | ↓ inhibits | Mechanistic | 1000.0 nM (Ki) | ChEMBL |
| CHEMBL4107804 | ↓ inhibits | Mechanistic | 3200.0 nM (IC50) | ChEMBL |
| CHEMBL4107907 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL4114159 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL4108338 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4107714 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4110311 | ↓ inhibits | Mechanistic | 9500.0 nM (IC50) | ChEMBL |
| CHEMBL4107559 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL4114106 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4109097 | ↓ inhibits | Mechanistic | 11700.0 nM (IC50) | ChEMBL |
| CHEMBL4108330 | ↓ inhibits | Mechanistic | 2300.0 nM (IC50) | ChEMBL |
| CHEMBL4109114 | ↓ inhibits | Mechanistic | 4500.0 nM (IC50) | ChEMBL |
| CHEMBL3961039 | ↓ inhibits | Mechanistic | 7300.0 nM (IC50) | ChEMBL |
| CHEMBL4112247 | ↓ inhibits | Mechanistic | 10700.0 nM (IC50) | ChEMBL |
| CHEMBL4109308 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL4109014 | ↓ inhibits | Mechanistic | 11820.0 nM (IC50) | ChEMBL |
| CHEMBL4108567 | ↓ inhibits | Mechanistic | 3800.0 nM (IC50) | ChEMBL |
| CHEMBL4111131 | ↓ inhibits | Mechanistic | 18000.0 nM (IC50) | ChEMBL |
| CHEMBL4115372 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL4106481 | ↓ inhibits | Mechanistic | 3050.0 nM (IC50) | ChEMBL |
| CHEMBL4108186 | ↓ inhibits | Mechanistic | 5610.0 nM (IC50) | ChEMBL |
| CHEMBL4115360 | ↓ inhibits | Mechanistic | 5800.0 nM (IC50) | ChEMBL |
| CHEMBL4114503 | ↓ inhibits | Mechanistic | 25300.0 nM (IC50) | ChEMBL |
| CHEMBL4108540 | ↓ inhibits | Mechanistic | 2970.0 nM (IC50) | ChEMBL |
| CHEMBL4109409 | ↓ inhibits | Mechanistic | 5750.0 nM (IC50) | ChEMBL |
| CHEMBL4109932 | ↓ inhibits | Mechanistic | 14300.0 nM (IC50) | ChEMBL |
| CHEMBL4106569 | ↓ inhibits | Mechanistic | 16800.0 nM (IC50) | ChEMBL |
Showing top 40 of 170 agents ranked by evidence tier.
PTGS1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CURCUMIN PYRAZOLE | ? unclear | Mechanistic | DGIdb | |
| BROMFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| FLURBIPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| DIFLUNISAL | ↓ inhibits | Mechanistic | DGIdb | |
| URSOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| NEPAFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| SALICYLIC ACID | ? unclear | Mechanistic | DGIdb | |
| IBUPROFEN, SODIUM SALT | ↓ inhibits | Mechanistic | DGIdb | |
| INDOMETHACIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| NAPROXEN ETEMESIL | ↓ inhibits | Mechanistic | DGIdb | |
| PIROXICAM-BETA-CYCLODEXTRIN | ↓ inhibits | Mechanistic | DGIdb | |
| SUPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| MECLOFENAMATE | ↓ inhibits | Mechanistic | DGIdb | |
| NITRIC OXIDE-RELEASING ACETYLSALICYLIC ACID DERIVATIVE | ? unclear | Mechanistic | DGIdb | |
| MEFENAMIC ACID | ↓ inhibits | Mechanistic | DGIdb | |
| FENOPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| PHENYLBUTAZONE | ↓ inhibits | Mechanistic | DGIdb | |
| APAZONE | ↓ inhibits | Mechanistic | DGIdb | |
| OXAPROZIN POTASSIUM | ↓ inhibits | Mechanistic | DGIdb | |
| FENOPROFEN CALCIUM | ↓ inhibits | Mechanistic | DGIdb | |
| ICOSAPENT ETHYL | ? unclear | Mechanistic | DGIdb | |
| (S)-ARN2508 | ↓ inhibits | Mechanistic | DGIdb | |
| SWE101 | ↓ inhibits | Mechanistic | DGIdb | |
| MELOXICAM | ↓ inhibits | Mechanistic | 2200.0 nM (IC50) | DGIdb |
| ISOXICAM | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC POTASSIUM | ↓ inhibits | Mechanistic | DGIdb | |
| TEPOXALIN | ↓ inhibits | Mechanistic | DGIdb | |
| IBUPROFEN LYSINE | ↓ inhibits | Mechanistic | DGIdb | |
| ACEMETACIN | ↓ inhibits | Mechanistic | DGIdb | |
| DERSALAZINE | ? unclear | Mechanistic | DGIdb | |
| FK-881 | ↓ inhibits | Mechanistic | DGIdb | |
| (R)-ARN2508 | ↓ inhibits | Mechanistic | DGIdb | |
| OXAPROZIN | ↓ inhibits | Mechanistic | DGIdb | |
| BENZYDAMINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ASPIRIN | ↓ inhibits | Mechanistic | DGIdb | |
| OLSALAZINE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| KETOROLAC TROMETHAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| SALSALATE | ? unclear | Mechanistic | DGIdb | |
| ANTIVIRAL AGENT | ? unclear | Mechanistic | DGIdb | |
| LORNOXICAM | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 281 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
Clopidogrel is a prescription medicine used to minimize blood clot formation in patients with cardiovascular disease, particularly those undergoing heart catheterization and stroke. A substantial amount of medical evidence has proven that patients with stroke or heart diseases can benefit from this ...
The goal of this study is to test if Savvy, a multimodal intervention (consisting of psychological exercises, a weekly pill organizer, and a text message reminder system) can improve medication adherence in stroke survivors. The main questions it aims to answer are: * Can the Savvy tool improve me...
The goal of this observational study is to use a genetic test to help doctors prescribe the most effective medications after a patient has a stroke. One type of stroke is caused by a blood clot in brain vessels. After a patient has this kind of stroke, they are often given a combination of two blood...
Unrecognized atrial fibrillation (AF) is a common cause of ischemic stroke. Implantable event monitors (ICM) are the gold standard for continuous heart rhythm monitoring but they have been implemented in very few patients after stroke due to high invasiveness and high costs. In this trial, patients...
Purpose The Y-SCOPE study aims to improve the health and recovery of young adults aged 18 to 65 who have experienced an ischemic stroke or a high-risk transient ischemic attack (TIA). By focusing on personalized care and lifestyle changes, the study seeks to reduce the chances of another stroke and ...
The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary prevention phase in patients with stroke, Moyamoya disease and Cerebral amyloid angiopathy, including adults of both sexes. The main questions it aims to ...
The goal of this clinical trial is to test a person-centred care transition support in people with stroke/TIA. The main questions it aims to answer are: * Does a multi-component care transition intervention have an effect on perceived quality of care transitions, health literacy, collected medicati...
This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but...
The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value. Participants will receive usual care...
The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.
The main objective of the study is to compare the benefit of optimised follow-up by nursing personnel from the vascular neurology department, including therapeutic follow-up and an educational program directed to the patient and a caregiving member of his social circle, with that of a typical follow...
The effectiveness of emergency management of acute ischemic stroke has improved considerably in recent years with thrombolysis and more recently thrombectomy. This improvement is accompanied by an increase in the number of stroke survivors. One of the major issues for these ever-increasing survivors...
The goal of this observational study is to investigate sex - differences in detection rate of atrial fibrillation after cryptogenic stroke (embolic stroke of unknown cause) - using an implantable cardiac rhythm monitor - and the treatment effects of oral anticoagulation on recurrent stroke, ischemic...
Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. The most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. The...
Introduction: Low- and middle-income countries, such as Brazil, are most impacted by the high burden of recurrent stroke. These countries also lack structured interventions to promote the adoption of healthy lifestyle behaviors in the context of stroke secondary prevention. In contrast, high-income ...
Searched directly from “Stroke (Secondary Prevention)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."